Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
KPV
Overview
A C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH) that retains potent anti-inflammatory activity without melanogenic effects. KPV inhibits NF-kB nuclear translocation and reduces production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6.
Mechanism of Action
It penetrates cell membranes and directly interacts with inflammatory signaling cascades, making it effective topically and orally for mucosal inflammation.
Research Summary & Key Findings
Preclinical studies demonstrated significant anti-inflammatory effects in colitis models, reducing mucosal inflammation and promoting epithelial barrier repair. Oral KPV-loaded nanoparticles showed targeted anti-inflammatory activity in the colon (Dalmasso et al., PLoS One, 2008). Investigated for inflammatory bowel disease, atopic dermatitis, and wound healing. Preclinical stage with limited human clinical data.
Clinical Status
KPV is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "KPV"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "KPV"
Registered interventional and observational studies, including status and phase.
- PubChem: "KPV"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Immune
Thymalin
InvestigationalA peptide bioregulator originally extracted from bovine thymus gland, consisting of a mixture of polypeptides that modul...
View detailsLL-37
Research PhaseThe only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein h...
View detailsVIP (Vasoactive Intestinal Peptide)
InvestigationalA 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts...
View detailsThymosin Alpha 1 (Zadaxin)
InvestigationalA 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) that serves as a potent immunomodul...
View detailsNo lawful pathway today
KPV is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.